Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback